Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc. (FOXO) generates news across healthcare services, behavioral health, biospecimen sourcing and biotechnology. Company announcements describe operations at its critical access hospital in East Tennessee, its behavioral health subsidiary, Myrtle Recovery Centers, its biospecimen provider Vector BioSource, Inc., and its biotechnology arm, FOXO Labs, Inc.
News items for FOXO often cover developments at Big South Fork Medical Center, including service expansions such as swing bed and wound care services and agreements like its Performance Network Agreement with Covenant Health to provide swing bed services within a broader performance network. Updates may also highlight patient volumes, service mix and new clinical offerings at the hospital.
FOXO’s behavioral health subsidiary, Myrtle Recovery Centers, Inc., appears frequently in company communications through license renewals, operational updates, and recognition from local and statewide organizations. News has included approval to receive Scott County Opioid Abatement Funds to support care for uninsured patients, as well as acknowledgments from associations such as the Rural Health Association of Tennessee.
On the life sciences side, FOXO issues press releases about its acquisition and growth of Vector BioSource, Inc., an information, data and biospecimen sourcing provider serving biotechnology, clinical research and pharmaceutical research sectors. These updates detail acquisition terms, revenue run-rate information, and planned funding for Vector’s growth initiatives.
FOXO also publishes news about FOXO Labs, Inc. and its epigenetics business, including the decision to pursue a spin-off of FOXO Labs, descriptions of its patent related to DNA epigenetic data, and its work on epigenetic biomarkers and AI-based wellness coaching concepts.
Corporate-level news for FOXO includes reverse stock split actions, changes to authorized share capital, preferred stock designations, and listing status updates, such as the transition of its common stock trading from NYSE American to the OTC market. Investors and observers can use the FOXO news feed on Stock Titan to follow these healthcare, biotechnology and corporate governance developments as they are disclosed in press releases and related SEC filings.
FOXO Technologies Inc. (AMEX: FOXO) has announced the postponement of its earnings conference call, with a subsequent press release to reveal the new date and time. This delay could indicate potential issues or uncertainty regarding the company's financial performance and outlook. FOXO operates at the intersection of technology and life insurance, focusing on epigenetic longevity science aimed at improving consumer underwriting processes through innovations like the FOXO Longevity Report™.
FOXO Technologies has announced a new managing general agency agreement between its subsidiary, FOXO LIFE, and Haven Life, a subsidiary of MassMutual. This strategic partnership aims to enhance FOXO LIFE's distribution of Haven Life insurance products through independent agents. This collaboration is set to expand FOXO LIFE's market reach, leveraging Haven Life's innovative digital purchasing experience in the life insurance sector. The announcement comes ahead of the NAILBA Annual Meeting, emphasizing FOXO's commitment to modernizing life insurance through technology.
FOXO Technologies Inc. (FOXO) announced it will report its financial results for the third quarter of 2022 on November 14, 2022, after market close. A conference call will be held at 3:15 p.m. Central time on the same day to discuss the results and recent business highlights. FOXO is focused on leveraging epigenetic technology to modernize the life insurance industry, utilizing AI to analyze DNA methylation for health biomarkers, enhancing the underwriting process, and improving consumer value prop through its FOXO Longevity Report.
FOXO Technologies Inc. (AMEX: FOXO) announced the recruitment of its first distribution partner, BGA Insurance, which represents over 4,000 independent agents in California. This partnership aims to promote longevity-focused life insurance products through FOXO LIFE. Additionally, James Grauel, Jr. has been appointed as Chief Distribution Officer to lead these efforts. The company will conduct agent recruitment events in Southern California starting October 19, 2022. The announcement follows FOXO's recent public trading debut with an enterprise value of approximately $369 million.
FOXO Technologies Inc. announced the completion of its business combination with Delwinds Insurance Acquisition Corp., with trading starting on the NYSE American under the symbol 'FOXO' from September 16, 2022. This strategic move aims to address key issues within the life insurance sector through epigenetic longevity science. FOXO's inaugural Managing General Agency relationship allows for marketing a range of life insurance products bundled with the FOXO Longevity Report™. The business combination received over 91% shareholder approval, underscoring strong investor confidence.